Compare Stocks → Will this $2 AI stock double overnight? (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CERCNYSE:IBIONASDAQ:KMDANASDAQ:KZROTCMKTS:SEOVF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCERCCerecor$12.01-11.8%$2.60$1.98▼$4.50$1.15B1.441.27 million shs107,494 shsIBIOiBio$1.72-2.8%$0.00$1.02▼$27.80$5.99M-3.513.19 million shs94,926 shsKMDAKamada$5.05-1.0%$5.78$4.08▼$6.53$290.24M1.0423,664 shs26,444 shsKZRKezar Life Sciences$0.79+0.3%$0.89$0.67▼$3.13$57.51M0.47699,931 shs421,160 shsSEOVFSernova$0.33$0.42$0.29▼$0.83$99.97M1.1619,754 shs29,167 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCERCCerecor-24.65%-23.75%+176.09%+185.27%+308.67%IBIOiBio-5.85%-11.50%+40.48%+176,999,900.00%+176,999,900.00%KMDAKamada+0.39%-1.92%-11.15%-13.12%+9.68%KZRKezar Life Sciences-3.55%-8.11%-9.55%-5.11%-68.50%SEOVFSernova+0.33%-13.29%-21.77%-27.28%-46.85%Tiny Biotech Stock Wins $75 Billion Patent (Ad)A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCERCCerecorN/AN/AN/AN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AN/AN/AN/AKMDAKamada4.1327 of 5 stars3.55.00.00.02.61.73.1KZRKezar Life Sciences3.9767 of 5 stars3.22.00.04.62.41.71.3SEOVFSernovaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCERCCerecorN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AKMDAKamada3.00Buy$11.00117.82% UpsideKZRKezar Life Sciences2.33Hold$11.001,292.41% UpsideSEOVFSernova2.00Hold$1.50355.24% UpsideCurrent Analyst RatingsLatest KZR, KMDA, CERC, IBIO, and SEOVF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024SEOVFSernovaRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform$1.503/15/2024KZRKezar Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/7/2024KMDAKamadaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCERCCerecor$6.70M172.10N/AN/A$0.22 per share54.59IBIOiBio$2.38M2.51N/AN/A$15.15 per share0.11KMDAKamada$142.52M2.04$0.42 per share11.91$4.25 per share1.19KZRKezar Life Sciences$7M8.22N/AN/A$2.58 per share0.31SEOVFSernovaN/AN/AN/AN/A$0.03 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCERCCerecor-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/AIBIOiBio-$65.01MN/A0.00∞N/AN/A-150.59%-52.83%N/AKMDAKamada$8.28M$0.1533.6712.32N/A5.81%5.66%3.57%5/22/2024 (Estimated)KZRKezar Life Sciences-$101.87M-$1.41N/AN/AN/AN/A-43.08%-37.59%5/9/2024 (Estimated)SEOVFSernova-$28.91M-$0.09N/A∞N/AN/A-226.64%-145.26%6/12/2024 (Estimated)Latest KZR, KMDA, CERC, IBIO, and SEOVF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q1 2024SEOVFSernovaN/A-$0.02-$0.02-$0.02N/AN/A3/14/2024Q4 2023KZRKezar Life Sciences-$0.39-$0.35+$0.04-$0.26N/AN/A3/6/2024Q4 2023KMDAKamada$0.05$0.09+$0.04$0.09$37.71 million$36.43 million2/9/2024Q2 2024IBIOiBioN/A-$2.42-$2.42-$0.42N/AN/A1/29/2024Q4 2023SEOVFSernovaN/A-$0.03-$0.03-$0.03N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCERCCerecorN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/ASEOVFSernovaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCERCCerecor0.792.192.18IBIOiBio0.040.910.91KMDAKamadaN/A3.431.64KZRKezar Life Sciences0.0511.6611.66SEOVFSernova0.141.201.20OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCERCCerecor62.84%IBIOiBio7.90%KMDAKamada20.38%KZRKezar Life Sciences67.90%SEOVFSernovaN/AInsider OwnershipCompanyInsider OwnershipCERCCerecor45.70%IBIOiBio1.12%KMDAKamada36.10%KZRKezar Life Sciences7.90%SEOVFSernovaN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCERCCerecor3196.01 millionN/ANot OptionableIBIOiBio263.48 million3.45 millionN/AKMDAKamada37857.47 million36.73 millionOptionableKZRKezar Life Sciences5872.80 million67.05 millionNot OptionableSEOVFSernovaN/A303.41 millionN/ANot OptionableKZR, KMDA, CERC, IBIO, and SEOVF HeadlinesSourceHeadlineSernova Names Nicholas Rossettos Interim CFOmarketwatch.com - March 11 at 1:39 PMSernova reports anticipated 2024 milestonesmsn.com - January 29 at 10:40 AMSernova gets FDA orphan drug, rare pediatric designations for hemophilia Amsn.com - November 27 at 8:15 PMClosing Bell: Sernova Corp flat on Tuesday (SVA)theglobeandmail.com - November 14 at 9:04 PMSernova Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congressfinance.yahoo.com - October 30 at 7:35 AMSernova Presents Compelling New Data on the Cell Pouch System™ as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual Meetingfinance.yahoo.com - September 29 at 1:00 PMSernova Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Devicefinance.yahoo.com - September 7 at 10:11 AMSernova Appoints Cynthia Pussinen as Chief Executivemarketwatch.com - September 5 at 4:32 PMSernova appoints CEOseekingalpha.com - September 5 at 4:32 PMSernova reports positive interim data for Cell Pouch Systemmassdevice.com - June 26 at 6:49 PMSernova (SVA) Receives a Buy from H.C. Wainwrightmarkets.businessinsider.com - June 26 at 8:00 AMSernova to Present Updated Interim Phase 1/2 Clinical Data on Cell Pouch System™ During Oral Presentation at American Diabetes Association 83rd Scientific Sessionsfinance.yahoo.com - June 22 at 6:01 PMSernova is significantly undervalued, says Echeloncantechletter.com - June 16 at 11:36 PMSernova to Participate in Upcoming Truist Securities Cell Therapy Symposiumfinance.yahoo.com - June 16 at 1:35 PMEchelon Wealth Partners Remains a Buy on Sernova (SVA)markets.businessinsider.com - June 15 at 3:50 PMSernova Announces Executive Alignment and Appoints New Board Chairfinance.yahoo.com - May 31 at 8:58 AMClosing Bell: Sernova Corp flat on Monday (SVA)theglobeandmail.com - May 8 at 9:43 PMSernova Corp. Announces Voting Results of the 2023 Annual General Meeting of Shareholdersthenewswire.com - April 28 at 3:38 PMClosing Bell: Sernova Corp flat on Thursday (SVA)theglobeandmail.com - April 28 at 10:37 AMConcerned Shareholders of Sernova Corp. Wish to Thank All Shareholdersfinance.yahoo.com - April 25 at 6:02 PMSernova Reminds Shareholders to Vote FOR the Eight Management Director Nominees Using ONLY the WHITE Management Proxythenewswire.com - April 21 at 12:40 PMProxy adviser backs diabetes device developer Sernova in fight against activist investorsmedtechdive.com - April 17 at 3:33 PMSernova to Present at 2023 Alliance for Regenerative Medicine Cell & Gene Meeting on the Medfinance.yahoo.com - April 10 at 8:20 AMSernova defends record after investors attack ‘sluggish’ progress of regenerative medicine implantmedtechdive.com - April 7 at 3:12 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideCan Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?April 10, 2024 7:55 AMView Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?All Headlines Company DescriptionsCerecorNASDAQ:CERCCerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.iBioNYSE:IBIOiBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.KamadaNASDAQ:KMDAKamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Kezar Life SciencesNASDAQ:KZRKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.SernovaOTCMKTS:SEOVFSernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.